Correspondence 0001104659-23-125236 from Miromatrix Medical Inc. (CIK 0001527096)
Miromatrix Medical Inc. (CIK 0001527096)
Date: Dec. 12, 2023 · CIK: 0001527096 · Accession: 0001104659-23-125236
AI Filing Summary & Sentiment
Referenced dates: December 11, 2023, November 30, 2023
Letter
VIA EDGAR Division of Corporation Finance Office of Mergers & Acquisitions Re: Miromatrix Medical Inc. Schedule 14D-9/A filed November 30, File No. 005-93461 SEC Comment Letter dated December 11, 2023
Dear Mr. Soares and Ms. Chalk:
This letter is being submitted on behalf of Miromatrix Medical Inc. (the “Company”) in response to comments from the staff of the Division of Corporation Finance (the “Staff”) of the Securities and Exchange Commission (the “Commission”) with respect to the Company’s above-referenced Schedule 14D-9 (as amended, the “Schedule 14D-9”), as set forth in the Staff’s letter dated December 11, 2023 (the “Comment Letter”).
The headings and numbered paragraphs below correspond to the headings and numbered paragraphs set forth in the Comment Letter. For the Staff’s convenience, we have set forth below in italics each of the numbered comments from the Comment Letter followed by the Company’s responses thereto in regular type.
Schedule 14D-9/A filed November 30, 2023
Summary of Piper Sandler’s Financial Analysis, page 28
1. Please expand your response to prior comment 3 to provide your analysis as to why you do not believe that a financial advisor engaged by your board of directors to provide advice with respect to a tender offer and whose analyses or conclusions are discussed in your Schedule 14D-9 is not "indirectly employed, retained, or to be compensated" to assist you to make your Schedule 14D-9 solicitation or recommendation under Item 1009(a) of Regulation S-K. In this regard, we refer you to Question 159.01 of the Division of Corporation Finance's "Tender Offer Rules and Schedules" Compliance and Disclosure Interpretations.
December 12, 2023
Page 2
Company Response: The Company acknowledges and accepts the Staff’s position set forth in response to Question 159.01 of its “Tender Offer Rules and Schedules” Compliance and Disclosure Interpretations (“CDI 159.01”). The Company hereby withdraws or amends its position set forth in its letter to the Staff dated November 30, 2023, to the extent such stated position was inconsistent with CDI 159.01. The Company further confirms that it has already included in the Schedule 14D-9 the information required under Item 1009(a) of Regulation M-A (taking into account the guidance in CDI 159.01) to be disclosed regarding Piper Sandler, including a description of material terms of employment, retainer or other arrangement for compensation.
We very much appreciate the Staff’s review of this filing. If you have any questions, please feel free to contact me at (612) 766-8577.
Respectfully,
FAEGRE DRINKER BIDDLE & REATH LLP
Show Raw Text
CORRESP
1
filename1.htm
Faegre Drinker Biddle & Reath LLP
2200 Wells Fargo Center
90 S. Seventh Street
Minneapolis, Minnesota 55402
+1 612 766 7000 main
+1 612 766 1600 fax
VIA EDGAR
December 12, 2023
Brian Soares
Christina Chalk
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Mergers & Acquisitions
100 F Street, NE
Washington, D.C. 20549
Re: Miromatrix Medical Inc.
Schedule 14D-9/A filed November 30,
2023
File No. 005-93461
SEC Comment Letter dated December 11, 2023
Dear Mr. Soares and Ms. Chalk:
This letter is being submitted
on behalf of Miromatrix Medical Inc. (the “Company”) in response to comments from the staff of the Division of Corporation
Finance (the “Staff”) of the Securities and Exchange Commission (the “Commission”) with respect
to the Company’s above-referenced Schedule 14D-9 (as amended, the “Schedule 14D-9”), as set forth in the Staff’s
letter dated December 11, 2023 (the “Comment Letter”).
The headings and numbered
paragraphs below correspond to the headings and numbered paragraphs set forth in the Comment Letter. For the Staff’s convenience,
we have set forth below in italics each of the numbered comments from the Comment Letter followed by the Company’s responses thereto
in regular type.
Schedule 14D-9/A filed November 30, 2023
Summary of Piper Sandler’s Financial
Analysis, page 28
1. Please expand your response to prior comment 3 to provide your analysis as to why you do not believe that a financial advisor engaged
by your board of directors to provide advice with respect to a tender offer and whose analyses or conclusions are discussed in your Schedule
14D-9 is not "indirectly employed, retained, or to be compensated" to assist you to make your Schedule 14D-9 solicitation or
recommendation under Item 1009(a) of Regulation S-K. In this regard, we refer you to Question 159.01 of the Division of Corporation
Finance's "Tender Offer Rules and Schedules" Compliance and Disclosure Interpretations.
December 12, 2023
Page 2
Company
Response: The Company acknowledges and accepts the Staff’s position set forth in response to Question 159.01 of its “Tender
Offer Rules and Schedules” Compliance and Disclosure Interpretations (“CDI 159.01”). The Company hereby
withdraws or amends its position set forth in its letter to the Staff dated November 30, 2023, to the extent such stated position
was inconsistent with CDI 159.01. The Company further confirms that it has already included in the Schedule 14D-9 the information required
under Item 1009(a) of Regulation M-A (taking into account the guidance in CDI 159.01) to be disclosed regarding Piper Sandler, including
a description of material terms of employment, retainer or other arrangement for compensation.
We very much appreciate the Staff’s review of this filing. If
you have any questions, please feel free to contact me at (612) 766-8577.
Respectfully,
FAEGRE DRINKER BIDDLE & REATH LLP
/s/ Steven C. Kennedy
Steven C. Kennedy
Enclosures
cc: Jeff Ross, Miromatrix Medical Inc.
Michael A. Stanchfield, Faegre Drinker Biddle &
Reath LLP
Brandon C. Mason, Faegre Drinker Biddle &
Reath LLP